XRCC1 Polymorphisms and Cancer Risk: A Meta-analysis of 38 Case-Control Studies

• Published in: Cancer epidemiology, biomarkers & prevention Vol. 14; no. 7; pp. 1810 - 1818
• Main Authors: Hu, Zhibin, Ma, Hongxia, Chen, Feng, Wei, Qingyi, Shen, Hongbing
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.07.2005
• Subjects: Biological and medical sciences; cancer; Case-Control Studies; DNA-Binding Proteins - genetics; Epidemiology; Ethnic Groups; Genotype; Humans; Medical sciences; meta-analysis; Neoplasms - genetics; polymorphism; Polymorphism, Genetic; susceptibility; Tumors; X-ray Repair Cross Complementing Protein 1; X-ray repair cross-complementing group 1 (XRCC1); Human; Genetic variability; Genotype; Case control study; Malignant tumor; Epidemiology; Repair gene; Metaanalysis; Cancerology; Risk factor; Genetics; Public health; Polymorphism
• ISSN: 1055-9965; 1538-7755
• DOI: 10.1158/1055-9965.EPI-04-0793

Several potential functional polymorphisms (Arg 194 Trp, Arg 280 His, Arg 399 Gln) in the DNA base excision repair gene X-ray repair cross-complementing group 1 ( XRCC1 ) have been implicated in cancer risk. Our meta-analysis on total of 11,957 cancer cases and 14,174 control subjects from 38 published case-control studies showed that the odds ratio (OR) for the variant genotypes (Trp/Trp + Arg/Trp) of the Arg 194 Trp polymorphism, compared with the wild-type homozygote (Arg/Arg), was 0.89 [95% confidence interval (95% CI), 0.81-0.98] for all tumor types without between-study heterogeneity. Similarly, the overall risk for the combined variant genotypes (His/His + Arg/His) of the Arg 280 His, compared with the wild homozygote (Arg/Arg), was 1.19 (95% CI, 1.00-1.42). However, there was no main effect in either recessive or dominant modeling for the Arg 399 Gln, and the variant Gln/Gln homozygote was not associated with overall cancer risk (OR, 1.01; 95% CI, 0.90-1.14). The analyses suggest that XRCC1 Arg 194 Trp, Arg 280 His polymorphisms may be biomarkers of cancer susceptibility and a single larger study with thousands of subjects and tissue-specific biochemical and biological characterization is warranted to further evaluate potential gene-to-gene and gene-to-environment interactions on XRCC1 polymorphisms and cancer risk.